Novartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the defensive again after it emerged a senior manager sold almost $1 million worth ...

The pharmaceutical company says it will continue to operate its production facility near Research Triangle Park.

Novartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that hasn’t stopped it making a strong start in the US market. Zolgensma (onasemnogene ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Last year, Novartis reported revenue from Zolgensma of $1.2 billion.

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Novartis-owned firm picks Durham over Illinois, Ireland for 200 jobs Multibillion-dollar ...

Novartis’ Durham facility produces Zolgensma, which treats spinal muscular atrophy, an inherited fatal disorder often referred to as SMA. In 2019, the Food and Drug Administration approved ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

Swiss pharmaceutical giant Novartis has exited one of its two state incentive deals for a gene therapies facility near Research Triangle Park. The North Carolina Economic Investment Committee on ...